Vetoquinol live
-
VETOQUINOL WINS THE ANIMAL PHARM’S AWARD FOR BEST EUROPEAN COMPANY 2020
08 Feb 2021February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm. -
VETOQUINOL ACQUIRES THE RIGHTS FOR PROFENDER® FROM ELANCO ANIMAL HEALTH FOR CANADA
08 Feb 2021February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal... -
2020 SALES: €427.5M (UP 8.0% AS REPORTED, UP 10.9% AT CONSTANT EXCHANGE RATE) ESSENTIALS SALES: €220.6M (UP 15.7% AS REPORTED, UP 17.3% AT CONSTANT EXCHANGE RATE)
21 Jan 2021Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams,... -
ORION ANIMAL HEALTH AND VETOQUINOL EXPAND COLLABORATION - VETOQUINOL TO DISTRIBUTE ORION’S CLEVOR® IN THE USA AND ORION TO DISTRIBUTE DRONTAL® AND PROFENDER® PRODUCTS IN FINLAND, HUNGARY AND ROMANIA
18 Jan 2021Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.
-
VETOQUINOL WINS THE ANIMAL PHARM’S AWARD FOR BEST EUROPEAN COMPANY 2020
08 Feb 2021February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm. -
VETOQUINOL ACQUIRES THE RIGHTS FOR PROFENDER® FROM ELANCO ANIMAL HEALTH FOR CANADA
08 Feb 2021February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health. -
2020 SALES: €427.5M (UP 8.0% AS REPORTED, UP 10.9% AT CONSTANT EXCHANGE RATE) ESSENTIALS SALES: €220.6M (UP 15.7% AS REPORTED, UP 17.3% AT CONSTANT EXCHANGE RATE)
21 Jan 2021Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.” -
ORION ANIMAL HEALTH AND VETOQUINOL EXPAND COLLABORATION - VETOQUINOL TO DISTRIBUTE ORION’S CLEVOR® IN THE USA AND ORION TO DISTRIBUTE DRONTAL® AND PROFENDER® PRODUCTS IN FINLAND, HUNGARY AND ROMANIA
18 Jan 2021Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.
-
21 january 2021
2020 Annual revenues (after market)
-
01 april 2021
Annual results (before market)
-
15 april 2021
2021 First quarter revenues (after market)
-
27 May 2021
Annual shareholders’ meeting